Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: Implications for human breast cancer

Oncogene

Volumn 29, Issue 23, 2010, Pages 3374-3385

  Pontier, S M ^a   Huck, L ^a   White, D E ^b   Rayment, J ^a   Sanguin Gendreau, V ^a   Hennessy, B ^c   Zuo, D ^a   St Arnaud, R ^d   Mills, G B ^c   Dedhar, S ^e   Marshall, C J ^b   Muller, W J ^a  

^a MCGILL UNIVERSITY   (Canada)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ErbB2; Integrin linked kinase; Mammary tumorigenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN LINKED KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; GENE DELETION; GENE MUTATION; GENE TARGETING; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 77953477155     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.86     Document Type: Article

References (47)

1. Ahmed F, Wyckoff J, Lin EY, Wang W, Wang Y, Hennighausen L et al. (2002). GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res 62: 7166-7169.
2. Akhtar N, Marlow R, Lambert E, Schatzmann F, Lowe ET, Cheung J et al. (2009). Molecular dissection of integrin signalling proteins in the control of mammary epithelial development and differentiation. Development 136: 1019-1027.
3. Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ. (2000). Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 97: 3444-3449.
4. Attwell S, Mills J, Troussard A, Wu C, Dedhar S. (2003). Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN. Mol Biol Cell 14: 4813-4825.
5. Attwell S, Roskelley C, Dedhar S. (2000). The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 19: 3811-3815.
6. Cowin P, Welch DR. (2007). Breast cancer progression: controversies and consensus in the molecular mechanisms of metastasis and EMT. J Mammary Gland Biol Neoplasia 12: 99-102.
7. D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B et al. (2000). The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 275: 32649-32657.
8. Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z et al. (2001). Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol 21: 1540-1551.
9. Dedhar S, Williams B, Hannigan G. (1999). Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol 9: 319-323.
10. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. (1998). Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 95: 11211-11216.
11. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788-3793.
12. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
13. Fielding AB, Dobreva I, McDonald PC, Foster LJ, Dedhar S. (2008). Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. J Cell Biol 180: 681-689. (Pubitemid 351397766)
14. Fukuda T, Chen K, Shi X, Wu C. (2003a). PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J Biol Chem 278: 51324-51333.
15. Fukuda T, Guo L, Shi X, Wu C. (2003b). CH-ILKBP regulates cell survival by facilitating the membrane translocation of protein kinase B/Akt. J Cell Biol 160: 1001-1008.
16. Hannigan G, Troussard AA, Dedhar S. (2005). Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5: 51-63.
17. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J et al. (1996). Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379: 91-96.
18. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H et al. (2007). Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13: 7421-7431.
19. Kawamoto S, Niwa H, Tashiro F, Sano S, Kondoh G, Takeda J et al. (2000). A novel reporter mouse strain that expresses enhanced green fluorescent protein upon Cre-mediated recombination. FEBS Lett 470: 263-268.
20. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ et al. (2005). Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4: 1681-1688.
21. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC et al. (2007). Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 104: 20302-20307.
22. Li N, Zhang Y, Naylor MJ, Schatzmann F, Maurer F, Wintermantel T et al. (2005). Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J 24: 1942-1953.
23. McDonald PC, Fielding AB, Dedhar S. (2008a). Integrin-linked kinase\essential roles in physiology and cancer biology. J Cell Sci 121: 3121-3132.
24. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V et al. (2008b). Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68: 1618-1624.
25. Mongroo PS, Johnstone CN, Naruszewicz I, Leung-Hagesteijn C, Sung RK, Carnio L et al. (2004). Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer. Oncogene 23: 8959-8970.
26. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J et al. (2000). Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97: 3207-3212.
27. Prigent SA, Gullick WJ. (1994). Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13: 2831-2841.
28. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. (2006). Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 4: 38.
29. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. (2008). Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 173: 1551-1565.
30. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J et al. (1997). Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem 272: 13937-13944.
31. Ranger JJ, Levy DE, Shahalizadeh S, Hallet M, Muller WJ. (2009). Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 69: 6823-6830.
32. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. (2003). Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100: 8430-8435.
33. Soltoff SP, Carraway 3rd KL, Prigent SA, Gullick WG, Cantley LC. (1994). ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14: 3550-3558.
34. Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD. (2001). Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 114: 1125-1136.
35. Soriano P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70-71.
36. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K et al. (2004). Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5: 79-90.
37. Terpstra L, Prud'homme J, Arabian A, Takeda S, Karsenty G, Dedhar S et al. (2003). Reduced chondrocyte proliferation and chondro-dysplasia in mice lacking the integrin-linked kinase in chondrocytes. J Cell Biol 162: 139-148.
38. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB et al. (2006). Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5: 2512-2521.
39. Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S. (2003). Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278: 22374-22378.
40. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA et al. (2006). Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 66: 393-403.
41. Tu Y, Li F, Goicoechea S, Wu C. (1999). The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol 19: 2425-2434.
42. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al. (2010). Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
43. Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD et al. (2008). ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 27: 910-920.
44. White DE, Cardiff RD, Dedhar S, Muller WJ. (2001). Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20: 7064-7072.
45. White DE, Coutu P, Shi YF, Tardif JC, Nattel S, St-Arnaud R et al. (2006). Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev 20: 2355-2360.
46. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U et al. (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6: 159-170.
47. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Yazici YD et al. (2005). Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 4: 1146-1156.